BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Life Raft Group - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The Life Raft Group
X-ORIGINAL-URL:https://liferaftgroup.org
X-WR-CALDESC:Events for The Life Raft Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210211T120000
DTEND;TZID=America/New_York:20210211T120000
DTSTAMP:20210124T180346Z
CREATED:20201103T133157Z
LAST-MODIFIED:20210124T180346Z
UID:10000093-1613044800-1613044800@liferaftgroup.org
SUMMARY:LRG Webcast Series: hPPGL Syndrome - a Misnomer with Consequences
DESCRIPTION:Dr. Annes will review the hPPGL Syndrome with particular focus on the underlying genetics basis and related tumor risks. He will review the benefits/limitations of genetic testing and pre-symptomatic screening\, including his personal experience directing Stanford’s Hereditary Neuroendocrine Neoplasia Clinic. Finally\, he will discuss opportunities for advancing hPPGL care and ongoing research. \nREGISTERPresenter:\nJustin Annes\, MD\, PhD\nAssociate Professor\, Stanford Department of Medicine \nDr. Annes is an Associate Professor in Stanford’s Department of Medicine and a Faculty Fellow in Stanford’s Chemistry\, Engineering & Medicine for Human Health Institute (ChEM-H). He obtained his BS from Haverford College (1996)\, MD PHD from New York University (1996) and trained in Internal Medicine\, Clinical Genetics and Chemical Biology at Brigham and Women’s Hospital / Harvard University (2011). Dr. Annes is director and founder of Stanford’s Hereditary Neuroendocrine Tumor Clinic (2012) which focuses on the longitudinal care of patients and families with inherited endocrine tumor syndromes\, primarily hPPGL\, MEN1 and MEN2. He participates in several neuroendocrine-focused patient advocacy / research foundations including The Pheo Para Alliance\, Neuroendocrine Tumor Research Foundation and the NIH Pediatric Wildtype GIST Clinic. His NIH-funded research program is positioned at the interface of endocrine pathophysiology\, synthetic chemistry and hereditary disease. The organizing principle of his research program is to harness the power of chemistry\, human tissue samples and animal disease models to deliver fundamental biologic insights and develop novel therapeutic leads for the treatment of endocrine disorders.
URL:https://liferaftgroup.org/event/lrg-webcast-hppgl-syndrome/
CATEGORIES:Education,Events
ATTACH;FMTTYPE=image/jpeg:https://liferaftgroup.org/wp-content/uploads/2020/11/annes1.jpg
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210224T120000
DTEND;TZID=America/New_York:20210224T120000
DTSTAMP:20210208T141853Z
CREATED:20210203T201450Z
LAST-MODIFIED:20210208T141853Z
UID:10000132-1614168000-1614168000@liferaftgroup.org
SUMMARY:Finding Biomarkers that Cause GIST
DESCRIPTION:From Research to Clinical Application\nEvery GIST patient is unique based on their biology and what treatment to which they will potentially respond. \nDr. Lori Rink\, Fox Chase Cancer Center\, and Dr. Inga-Marie Schaefer\, Brigham & Women’s Hospital\, are two researchers who are making discoveries in their respective laboratories to uncover the unique biomarkers in GIST that will be future drug targets. \nDr. Margaret von Mehren\, Fox Chase Cancer Center\, will moderate the webinar and help the audience understand why these important discoveries in the lab are important to clinicians. This concept of translational medicine is an important field as it helps bring advances into the clinic that can directly impact the survival of GIST patients. \nREGISTERAbout the Presenters\nLori Rink\, PhD\nAssistant Professor\, Molecular Therapeutics\, Fox Chase Cancer Center. Dr. Rink studied at the Biology at the University of Scranton  and  received her doctorate in  for a Doctorate in Molecular Biology from Temple University followed by a post-doctoral fellowship at Fox Chase Cancer Center.  She is an Assistant Professor in the Molecular Therapeutic program. Along with Dr. von Mehren\, two graduate students\, and a post-doctoral fellow\, Dr. Rink’s lab is dedicated to investigating why some GIST patients eventually develop a resistance to Gleevec\, discovering combinations of drugs that will attack GIST\, and identifying markers that could predict how patients will respond to Gleevec. \nInga-Marie Schaefer\, MD\nAssociate Pathologist\, Brigham & Women’s Hospital\, Instructor in Pathology\, Harvard Medical School\nDr. Schaefer is an instructor at the Department of Pathology at Brigham and Women’s Hospital\, Harvard Medical School in Boston\, MA. After graduating with an M.D. degree from Georg-August-University Goettingen in Germany\, she trained in Anatomic Pathology in Germany and at Brigham and Women’s Hospital. Her post-doctoral research in Dr. Jonathan Fletcher’s translational sarcoma laboratory focused on characterizing mechanisms of genomic progression in GIST/sarcoma\, combining diagnostics\, biology\, and genetics. Dr. Schaefer is now evaluating mechanisms of incremental cell cycle dysregulation in GIST progression. \n\nAbout the Moderator\nMargaret von Mehren\, MD\nAssociate Professor\, Director of Sarcoma\, Fox Chase Cancer Center\nDr. von Mehren matriculated at Georgetown University in Washington\, DC\, where she majored in Biology and minored in Philosophy\, and graduating in 1985 with honors. She received her medical degree from Albany Medical College in Albany\, NY. Dr. von Mehren completed an internship and residency at New York University Medical Center in New York before moving to Philadelphia for her fellowship in medical oncology at the Fox Chase Cancer Center and Temple University. After completing fellowship\, Dr. von Mehren joined the faculty of the department of Medical Oncology at Fox Chase Cancer Center where she remains today as and Associate Professor and the director of the Sarcoma program. She is a member of the NCCN panel for soft tissue sarcomas and GIST task force\, as well as the Intergroup GIST Task force. She also volunteers at the NIH Pediatric Wildtype GIST clinic biannually.
URL:https://liferaftgroup.org/event/finding-biomarkers-that-cause-gist/
CATEGORIES:Education,Events
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
END:VCALENDAR